Literature DB >> 25737331

High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.

Clare Tanton1, Kate Soldan2, Simon Beddows3, Catherine H Mercer4, Jo Waller5, Nigel Field4, Soazig Clifton6, Andrew J Copas4, Kavita Panwar3, Precious Manyenga3, Filomeno da Silva3, Kaye Wellings7, Catherine A Ison8, Anne M Johnson4, Pam Sonnenberg4.   

Abstract

BACKGROUND: The third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3) provides an opportunity to explore high-risk human papillomavirus (HR-HPV) and uptake of cervical screening and HPV vaccination in the general population.
METHODS: Natsal-3, a probability sample survey of men and women ages 16 to 74, resident in Britain, interviewed 8,869 women in 2010 to 2012. We explored risk factors for HR-HPV (in urine from 2,569 sexually experienced women ages 16 to 44), nonattendance for cervical screening in the past 5 years, and noncompletion of HPV catch-up vaccination.
RESULTS: HR-HPV was associated with increasing numbers of lifetime partners, younger age, increasing area-level deprivation, and smoking. Screening nonattendance was associated with younger and older age, increasing area-level deprivation (age-adjusted OR 1.91, 95% confidence interval, 1.48-2.47 for living in most vs. least deprived two quintiles), Asian/Asian British ethnicity (1.96, 1.32-2.90), smoking (1.97, 1.57-2.47), and reporting no partner in the past 5 years (2.45, 1.67-3.61 vs. 1 partner) but not with HR-HPV (1.35, 0.79-2.31). Lower uptake of HPV catch-up vaccination was associated with increasing area-level deprivation, non-white ethnicity, smoking, and increasing lifetime partners.
CONCLUSIONS: Socioeconomic markers and smoking were associated with HR-HPV positivity, nonattendance for cervical screening, and noncompletion of catch-up HPV vaccination. IMPACT: The cervical screening program needs to engage those missing HPV catch-up vaccination to avoid a potential widening of cervical cancer disparities in these cohorts. As some screening nonattenders are at low risk for HR-HPV, tailored approaches may be appropriate to increase screening among higher-risk women. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25737331      PMCID: PMC4435666          DOI: 10.1158/1055-9965.EPI-14-1333

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  Validity of women's self-reports of cancer screening test utilization in a managed care population.

Authors:  Lee S Caplan; David V McQueen; Judith R Qualters; Marilyn Leff; Carol Garrett; Ned Calonge
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-11       Impact factor: 4.254

2.  Achieving high and equitable coverage of adolescent HPV vaccine in Scotland.

Authors:  Katy Sinka; Kimberley Kavanagh; Ruth Gordon; John Love; Alison Potts; Martin Donaghy; Chris Robertson
Journal:  J Epidemiol Community Health       Date:  2013-08-28       Impact factor: 3.710

3.  Barriers to cervical cancer screening attendance in England: a population-based survey.

Authors:  Jo Waller; Marta Bartoszek; Laura Marlow; Jane Wardle
Journal:  J Med Screen       Date:  2009       Impact factor: 2.136

4.  Lesbians and cervical screening.

Authors:  J V Bailey; J Kavanagh; C Owen; K A McLean; C J Skinner
Journal:  Br J Gen Pract       Date:  2000-06       Impact factor: 5.386

5.  Increasing rates of cervical cancer in young women in England: an analysis of national data 1982-2006.

Authors:  G Foley; R Alston; M Geraci; L Brabin; H Kitchener; J Birch
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

Review 6.  Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis.

Authors:  Neha Pathak; Julie Dodds; Javier Zamora; Khalid Khan
Journal:  BMJ       Date:  2014-09-16

7.  Monitoring human papillomavirus prevalence in urine samples: a review.

Authors:  Espen Enerly; Cecilia Olofsson; Mari Nygård
Journal:  Clin Epidemiol       Date:  2013-03-12       Impact factor: 4.790

8.  Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data.

Authors:  Kath Moser; Julietta Patnick; Valerie Beral
Journal:  BMJ       Date:  2009-06-16

9.  Economic evaluation of human papillomavirus vaccination in the United Kingdom.

Authors:  Mark Jit; Yoon Hong Choi; W John Edmunds
Journal:  BMJ       Date:  2008-07-17

10.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories.

Authors:  P Sasieni; J Adams; J Cuzick
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  11 in total

1.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

Review 2.  Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.

Authors:  Siaw Shi Boon; Ho Yin Luk; Chuanyun Xiao; Zigui Chen; Paul Kay Sheung Chan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

3.  The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents.

Authors:  Luisa Del Río-Ospina; Sara Cecilia Soto-De León; Milena Camargo; Ricardo Sánchez; Cindy Lizeth Mancilla; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

4.  Association between mothers' screening uptake and daughters' HPV vaccination: a quasi-experimental study on the effect of an active invitation campaign.

Authors:  Francesco Venturelli; Flavia Baldacchini; Cinzia Campari; Cinzia Perilli; Maria Grazia Pascucci; Alba Carola Finarelli; Luigi Moscara; Paolo Giorgi Rossi
Journal:  BMJ Open       Date:  2017-09-25       Impact factor: 2.692

5.  Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study.

Authors:  Helen C Johnson; Erin I Lafferty; Rosalind M Eggo; Karly Louie; Kate Soldan; Jo Waller; W John Edmunds
Journal:  Lancet Public Health       Date:  2017-12-19

6.  Impact and acceptability of self-consent procedures for the school-based human papillomavirus vaccine: a mixed-methods study protocol.

Authors:  Suzanne Audrey; Harriet Batista Ferrer; Joanne Ferrie; Karen Evans; Michael Bell; Julie Yates; Marion Roderick; John MacLeod; Matthew Hickman
Journal:  BMJ Open       Date:  2018-03-03       Impact factor: 2.692

7.  Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.

Authors:  Pam Sonnenberg; Clare Tanton; David Mesher; Eleanor King; Simon Beddows; Nigel Field; Catherine H Mercer; Kate Soldan; Anne M Johnson
Journal:  Sex Transm Infect       Date:  2019-02-05       Impact factor: 3.519

8.  The Effect of Health Education on Adolescents' Awareness of HPV Infections and Attitudes towards HPV Vaccination in Greece.

Authors:  Ioannis Thanasas; Giagkos Lavranos; Pinelopi Gkogkou; Dimitrios Paraskevis
Journal:  Int J Environ Res Public Health       Date:  2022-01-03       Impact factor: 3.390

9.  The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.

Authors:  Francesca Pesola; Christopher Mathews; Matejka Rebolj; David Mesher; Kate Soldan; Henry Kitchener
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

10.  Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.

Authors:  Clare Tanton; David Mesher; Simon Beddows; Kate Soldan; Soazig Clifton; Kavita Panwar; Nigel Field; Catherine H Mercer; Anne M Johnson; Pam Sonnenberg
Journal:  Papillomavirus Res       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.